UroGen Pharma Ltd. Other Selling, General and Administrative Expense
UroGen Pharma Ltd. (URGN) reported Other Selling, General and Administrative Expense of $1.33 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherSellingGeneralAndAdministrativeExpense · last filed 2026-05-06
- UroGen Pharma Ltd. other selling, general and administrative expense for the quarter ending 2026-03-31 was $1.33M, a 22.26% increase year-over-year.
- UroGen Pharma Ltd. other selling, general and administrative expense for the quarter ending 2025-03-31 was $1.09M.
| Period end | Other Selling, General and Administrative Expense 3 month |
|---|---|
| 2026-03-31 | $1.33M 10-Q · filed 2026-05-06 |
| 2025-03-31 | $1.09M 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |